Craving Biohaven

Biohaven Pharmaceutical Holding Co. Ltd. raised a tranched $80 million private round on its management team’s track record of bringing neurology compounds through the clinic, and the range of both Orphan and common indications the company’s pipeline can address.

Venrock led the round and was joined by RA Capital, Vivo Capital, Aisling Capital, Rock Springs Capital, Knoll Capital Management, Osage University Partners, Aperture Venture Partners, Connecticut Innovations, Litmore Capital, John W. Childs, Greg Bailey and two undisclosed pharmas. ...